South East Asia Market for Branded Generics Analysed in New FirstWord Report Available at

04 Jun 2012 • by Natalie Aster

LONDON – With its fast-growing, young population and projected pharmaceutical sales in excess of $20 billion in 2014, countries in the Association of South East Asian Nations (ASEAN) represent a great opportunity for Pharma.

However, with regional marketing practices, uncertain production values of locally manufactured generics and a huge diversity in healthcare delivery across ten nations of varying income levels, there are also great challenges.

Despite the disadvantages large multinationals face, major pharmaceutical companies are diving into the region, focusing on revenue from new chemical entities and developing ‘branded’ generics as key investments.

New market report "Branded Generics in South East Asia: Current and Future Opportunities" elaborated by FirstWord has been recently published by Market Publishers Ltd.

Report Details:

Branded Generics in South East Asia: Current and Future Opportunities
Published: April, 2012
Pages: 78
Price: US$ 1.495,00

The report focuses on branded generics and new chemical entity (NCE) revenues and is based on interviews with ten of the region’s most experienced industry experts. It describes the current state-of-play, the future of branded generics and the physician, prescriber and patient dynamics that govern drug dispensing.

More new market research reports by the publisher can be found at FirstWord page.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970